JMP Securities Starts Aclaris Therapeutis (ACRS) at Market Outperform
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
JMP Securities initiated coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Market Outperform rating and a price target of $34.00.
Shares of Aclaris Therapeutis closed at $25.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aclaris Therapeutics (ACRS) Commences ATI-50001 Phase 1
- Oppenheimer Assumes OvaScience (OVAS) at Perform
- Oppenheimer Assumes Endo International plc (ENDP) at Perform
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesJMP Securities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!